Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice

被引:45
作者
Nagai, E [1 ]
Ogawa, T [1 ]
Kielian, T [1 ]
Ikubo, A [1 ]
Suzuki, T [1 ]
机构
[1] Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66160 USA
关键词
GM-CSF gene; adenovirus; cancer; vaccine; therapy;
D O I
10.1007/s002620050506
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The specific aim of this study was to examine the prophylactic as well as the therapeutic efficacies of irradiated mouse CT26 colon cancer cells, infected with recombinant adenoviruses harboring cDNAs specific for granulocyte macrophage-colony-stimulating factor (GM-CSF), interferon (IFN-gamma) and monocyte chemotactic protein1 (MCP-1). Results showed that turner cells secrete the respective cytokines for several days after infection and subsequent irradiation. Vaccination with irradiated GM-CSF-secreting CT26 cells protected 90% of syngeneic mice challenged with live parental cells. On the other hand, vaccination with irradiated IFN gamma or MCP-1-secreting CT26 cells totally failed to protect mice from tumor development after challenge with parental cells. None of the tumor-free mice initially vaccinated with irradiated GM-CSF-producing CT26 cells developed tumor upon repeated challenge with parental cells during the entire observation period. The establishment of specific and long-lasting antitumor immunity following vaccination with GM-CSF-producing turner cells requires the simultaneous presence of GM-CSF and tumor antigen at the vaccine site. Depletion of CD8(+) cells, but not CD4(+) cells, blocked the vaccine efficacy of GM-CSF-producing tumor cells. Subcutaneous injection of irradiated GM-CSF-producing CT26 cells also effectively prevented the growth of a small load of parental tumor that was implanted 3 days earlier or the development of metastatic foci in the lung from intravenously injected parental cells either 7 days before or 3 days after vaccination. Our data thus show that, in these experimental turner models, subcutaneous injection of irradiated tumor cells adenovirally, transduced with the GM-CSF gene lends not only to prevention of growth of subsequently implanted tumor but also to elimination of pre-existing and metastatic tumors.
引用
收藏
页码:72 / 80
页数:9
相关论文
共 55 条
[31]   PURIFICATION AND CHARACTERIZATION OF A NOVEL MONOCYTE CHEMOTACTIC AND ACTIVATING FACTOR PRODUCED BY A HUMAN MYELOMONOCYTIC CELL-LINE [J].
MATSUSHIMA, K ;
LARSEN, CG ;
DUBOIS, GC ;
OPPENHEIM, JJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (04) :1485-1490
[32]  
MELANI C, 1994, NAT IMMUN, V13, P76
[33]   A HUMAN-MELANOMA CELL-LINE TRANSDUCED WITH AN INTERLEUKIN-4 GENE BY A RETROVIRAL VECTOR RELEASES BIOLOGICALLY-ACTIVE IL-4 AND MAINTAINS THE ORIGINAL TUMOR ANTIGENIC PHENOTYPE [J].
MELANI, C ;
SULESUSO, J ;
ARIENTI, F ;
MACCALLI, C ;
PASSERINI, F ;
COLOMBO, MP ;
PARMIANI, G .
HUMAN GENE THERAPY, 1995, 6 (11) :1427-1436
[34]   THE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTORS [J].
METCALF, D .
SCIENCE, 1985, 229 (4708) :16-22
[35]   INTRODUCTION OF MURINE IL-4 GENE INTO B16(F10) MELANOMA TUMORS BY DIRECT GENE-TRANSFER WITH DNA-LIPOSOME COMPLEXES [J].
MISSOL, E ;
SOCHANIK, A ;
SZALA, S .
CANCER LETTERS, 1995, 97 (02) :189-193
[36]   PROLONGATION OF SURVIVAL IN METASTATIC MELANOMA AFTER ACTIVE SPECIFIC IMMUNOTHERAPY WITH A NEW POLYVALENT MELANOMA VACCINE [J].
MORTON, DL ;
FOSHAG, LJ ;
HOON, DSB ;
NIZZE, JA ;
WANEK, LA ;
CHANG, C ;
DAVTYAN, DG ;
GUPTA, RK ;
ELASHOFF, R ;
IRIE, RF .
ANNALS OF SURGERY, 1992, 216 (04) :463-482
[37]  
OGASAWARA M, 1993, CANCER RES, V53, P3561
[38]   IN-VITRO AND IN-VIVO GROWTH OF B16F10 MELANOMA-CELLS TRANSFECTED WITH INTERLEUKIN-4 CDNA AND GENE-THERAPY WITH THE TRANSFECTANT [J].
OHIRA, T ;
OHE, Y ;
HEIKE, Y ;
PODACK, ER ;
OLSEN, KJ ;
NISHIO, F ;
NISHIO, M ;
MIYAHARA, Y ;
FUNAYAMA, Y ;
OGASAWARA, H ;
ARIOKA, H ;
KUNIKANE, H ;
FUKUDA, M ;
KATO, H ;
SAIJO, N .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1994, 120 (11) :631-635
[39]  
PACE JL, 1981, J IMMUNOL, V126, P1863
[40]  
PORGADOR A, 1995, CANCER RES, V55, P4941